Partnership Extends Luina Bio’s Influence in the Industry to Asia
Brisbane, Queensland, Australia – 31 July 2018 – – Luina Bio, a leading biopharmaceutical manufacturing company in Australia, today announced it will develop and produce an innovative bacterial drug product for Genome & Company to support its clinical trials programme. The relationship signals Luina Bio’s first foray into Asia and further establishes its global leadership in the current Good Manufacturing Practise for microbiome projects.
Genome & Company is one of Korea’s most advanced biotechs in the microbiome field. It researches and develops dietary supplements, cosmeceuticals, and drugs using microbiome – including probiotics, cosmetics, and medicines.
Through this partnership, Luina Bio will supply the bacterial drug candidate to help Genome & Company to develop its pipeline as a life-saving medicine.
“We chose to work with Luina Bio because of its proven record of successful with microbiome projects. They are the right partner for us because they offer a fully integrated manufacturing service – from process development to assistance with regulatory compliance submissions,” said Jisoo Pae, chief executive officer of Genome & Company.
As the only bacterial contract manufacturing organization in Australia, Luina Bio has established itself as a leader in quality, reliability and innovation in the field of bacterial biomanufacturing and prides itself on its highly flexible approach to client service along with competitive pricing. Luina Bio offers an inclusive set of services including:
- Biopharmaceutical contract manufacturing;
- GMP manufacture of recombinant proteins and vaccines;
- Microbial products; and
- Production of GMP material for pre-clinical studies and clinical trial material batches for Phase 1, 2 and 3 clinical studies.
“We look forward to a long-time relationship with Genome & Company to assist them in getting their products ready for commercial production to benefit consumers,” said Les Tillack, Chief Executive Officer of Luina Bio. “This partnership allows Luina Bio to continue growing our portfolio of microbiome projects – each of which focuses on providing clients with world class pharmaceutical research performance and product development with the highest standards in service, reliability, safety and cost containment at the forefront.”
Ends.
Download Media Release Here: Press Release – LB and g&c_310718
FOR MORE INFORMATION, PLEASE CONTACT:
Chris Burrell, Executive Chair, Luina Bio
+61 (0)417 832 153
chris.burrell@luinabio.com.au
